- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04341480
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) emerged at December 2019 in Wuhan, Hubei Province, China. This infectious disease soon caused a large global outbreak and became a major public health issue. As of 19:00, 12 March 2020, the total number of confirmed cases of SARS-CoV-2 in China has reached 80982 with 3173 death, and 110 other countries have officially reported 45164 cases of SARS-CoV-2 infection with 1520 death.
In this particular time, only patients with SARS-CoV-2 or other diseases with an emergency condition were receipted by most of the hospitals in Hubei Province, even in many other regions of China. The delayed treatment for many chronic diseases, such as malignant tumors, is an increasing serious problem. One major concern was that patients with malignant tumors were generally older in age with low immunity. Preliminary study has shown that cancer patients are most susceptible to infect SARS-CoV-2 and more likely to develop a severe pneumonia. But many other researches suspected that conclusion. Moreover, many of the patients with malignant tumors are facing short term death from tumors rather than the risk of infection. Nevertheless, there is not sufficient evidence to insure the safety of chemotherapy in high-risk region of COVID-19, and there is also not sufficient information to judge which patients' tumor therapy can be appropriately delayed. Here the investigators investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is 18 to 80 years old female.
- Patient must have histologically confirmed either type of gynecological malignancies.
- Chemotherapy must be essential for the patient.
Exclusion Criteria:
- Diagnosed or suspected patients with covid-19 pneumonia, according to the symptom, nucleic acid tests, antibody tests for SARS-CoV-2, or CT scan of the lungs.
- Patient has a prior SARS-CoV-2 infection without clinical cure for 28 days.
- Patient has close contact with diagnosed or suspected SARS-CoV-2 infected person within 14 days.
- Patient has inadequate general condition, severe complication or organ dysfunction not fit for chemotherapy (based on the judgment of researchers).
- Patient or the family refuses to sign the informed consent.
- Patient does not cooperate in following up.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Chemotherapy group
Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital.
Total observation duration is 6 weeks.
|
Routine chemotherapy for individual tumor type.
|
Control group
No treatment, based on patient's choice.
Total observation duration is 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SARS-CoV-2 infection
Time Frame: through study completion, an average of 3 months.
|
Incidence rate of SARS-CoV-2 infection within the whole period of the study.
|
through study completion, an average of 3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: 6 weeks after enrollment.
|
Tumor response by determining changes (PD, SD, PR, CR) according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1
|
6 weeks after enrollment.
|
Safety and tolerability of chemotherapy as measured by the Common Terminology
Time Frame: through study completion, an average of 3 months.
|
Safety and tolerability of chemotherapy as measured by the Common Terminology Criteria for Adverse Events (version 4.0)
|
through study completion, an average of 3 months.
|
Quality of Life (QOL) measures using Functional Assessment of Cancer Therapy (FACT- ovarian cancer)
Time Frame: through study completion, an average of 3 months.
|
To evaluate quality of life (QOL) for the subjects undergoing this treatment, using validated tools. QOL will be assessed every 3 months during treatment course. [Functional Assessment of Cancer Therapy - Ovarian Cancer questionnaire (score range from 0 to 160. Higher scores represent better quality of life. questionnaire core-30 (QLQ-C30). |
through study completion, an average of 3 months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-TJ-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gynecological Cancer
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownGynecological CancerChina
-
Lena NilssonCompleted
-
University of ChesterCompleted
-
Universiti Putra MalaysiaNot yet recruitingGynecological Cancer | Elective SurgeryMalaysia
-
Rajavithi HospitalRecruitingPostoperative Outcomes | Whey Protein | Gynecological Cancer SurgeryThailand
-
Sichuan Cancer Hospital and Research InstituteRecruitingGynecological CancerChina
-
University Hospital, BordeauxCompleted
-
Centre Francois BaclesseLigue contre le cancer, FranceRecruitingLong Term Cancer Side Effects | Supportive Care in Cancer | Cancer Survivorship Care Plan | Advanced Nurse Practitioner | Pelvic Gynecological CancerFrance
-
IRCCS San RaffaeleRecruitingGynecological TumorsItaly
-
Tanta UniversityCompleted
Clinical Trials on Chemotherapy
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingColorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the LungUnited States, Canada
-
International Atomic Energy AgencyCompletedNon Small Cell Lung CancerChile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
-
Ping LiangNot yet recruitingChemotherapy | Liver Metastases | Colorectal Carcinoma
-
Second Affiliated Hospital, School of Medicine,...UnknownUnresectable Gastric Cancer | Successful Conversion Rate of OperationChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Yantai Yuhuangding HospitalRecruiting
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
Ruijin HospitalNot yet recruitingGastric Cancer | Neoadjuvant ChemotherapyChina